Newborns From Patients Treated With ART (Assisted Reproductive Technology)

NCT03993158 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Zhengzhou University

Phase

Observational

Started

2010-01-01

Last updated

2026-05-27

Condition(s) studied

Health Related

Study summary

The Prospective Cohort Study for Newborns from patients treated with ART was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, China.

Eligibility

Sex

ALL

Min age

0 Weeks

Max age

40 Years

Healthy volunteers

Inclusion Criteria: * All newborns from patients treated with ART in our center. Exclusion Criteria: \-

Primary outcome measure(s)

Birth weight — At delivery
Weight of newborns recorded in Kilogram
Number of newborns with Congenital malformations — At delivery
Any newborns with Congenital malformations will be recorded

Trial sites (1)

Facility	City	Region	Status
Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions Recruiting

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch Starting soon

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL Recruiting

Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer Starting soon

Pro-urokinase for Extended-Window Posterior Circulation Stroke Starting soon

Other trials for the same condition

PCOS (Polycystic Ovarian Syndrome) Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03993158 on ClinicalTrials.gov ↗ ← All trials in China